Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ally Financial Inc (ALLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ally Financial Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Ally Financial Inc trades at $44.13 (market cap $13.92B). The key difference: Ally Financial Inc is far larger — about 3.1× ACADIA Pharmaceuticals Inc.'s market cap, and Ally Financial Inc pays a 2.64% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ALLY | |
|---|---|---|
Market Cap | $4.49B | $13.92B |
Sector | Health | Financials |
52-Week High | $28.06 | $47.25 |
52-Week Low | $20.06 | $35.96 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Ally Financial (ALLY) trades at $45.40, up 0.18% with strong analyst support (68% buy ratings) and a $54 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q3 2025-Q1 2026. Fundamentals remain solid with a P/E of 11.22 and net income margin of 14.9%, though revenue has declined from $9.2B in 2022 to $8.77B in 2025. Recent corporate developments include a $0.30 dividend payment and upcoming Q2 2026 earnings release on July 21, 2026.
ALLY presents a compelling value opportunity with attractive valuation metrics and consistent earnings outperformance. The primary investment thesis centers on the company's dominant auto lending position and shareholder returns via dividends. Key risks include revenue stagnation, macroeconomic sensitivity to interest rates, and competitive pressure from digital banking disruptors. Upside potential exists if Q2 2026 earnings meet or exceed the $1.26 EPS estimate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →
